Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
Introduction The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation. Methods Eligible for study participa...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2008-09, Vol.134 (9), p.961-968 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 968 |
|---|---|
| container_issue | 9 |
| container_start_page | 961 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 134 |
| creator | Broeyer, F. J. F. Osanto, S. Ritsema van Eck, H. J. van Steijn, A. Q. M. J. Ballieux, B. E. P. B. Schoemaker, R. C. Cohen, A. F. Burggraaf, J. |
| description | Introduction
The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.
Methods
Eligible for study participation were patients, without known cardiologic abnormalities who did not use cardiotoxic medication (except for ANT-therapy), who had previously completed at least three cycles of anthracyclin-containing chemotherapy (
n
= 14) and patients who were ANT-naïve and who were scheduled to receive doxorubicin-containing chemotherapy (
n
= 12). Seven patients in this last group also completed at least three cycles and were available for follow-up assessments; thus a total population of 21 patients (12F/9M) completed at least three courses ANT-chemotherapy. In these patients blood samples and ECG-recordings were taken within 6 months after completion of ANT-therapy. In 12 patients (10F/2M) assessments were also done before, immediately afterwards and at 24 h after each course of ANT.
Results and Conclusions
In the patients who completed chemotherapy, NT-proBNP was 277% (
n
= 21; 95% CI: 86–661%,
P
|
| doi_str_mv | 10.1007/s00432-008-0372-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2515587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1531673081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-2e61e2de8e8515df4ff842dcc0a786830f479404f660e68b18d9aaa23c6a09e73</originalsourceid><addsrcrecordid>eNp1kUtLxDAUhYMoOj5-gBspgsvqzaNtuhFEfIHoRtfhTprMRDvNmHTE-femzODowlVI7nfPOeQQckzhnAJUFxFAcJYDyBx4xXK5RUZ0eKGcF9tkBLSiecFouUf2Y3yDdC8qtkv2qOSC1wWMyNPNJ7YL7J3vMm-zsfMzDO8mxMz6kGkMjfO9_3La9csBwK6fBtRL3bouH2M0TaanZub7qQk4Xx6SHYttNEfr84C83t68XN_nj893D9dXj7kWddXnzJTUsMZIIwtaNFZYKwVrtAasZCk5WFHVAoQtSzClHFPZ1IjIuC4RalPxA3K50p0vxjPTaNP1AVs1Dy7FXyqPTv2ddG6qJv5TseRXyEHgdC0Q_MfCxF69-UXoUmbFGBSUCSETRFeQDj7GYOyPAQU1NKBWDajUgBoaUMPOye9km431lyfgbA1g1NjagJ128YdL5lIIOiRkKy6mUTcxYZPwf_dvzrqf0w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220512448</pqid></control><display><type>article</type><title>Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Broeyer, F. J. F. ; Osanto, S. ; Ritsema van Eck, H. J. ; van Steijn, A. Q. M. J. ; Ballieux, B. E. P. B. ; Schoemaker, R. C. ; Cohen, A. F. ; Burggraaf, J.</creator><creatorcontrib>Broeyer, F. J. F. ; Osanto, S. ; Ritsema van Eck, H. J. ; van Steijn, A. Q. M. J. ; Ballieux, B. E. P. B. ; Schoemaker, R. C. ; Cohen, A. F. ; Burggraaf, J.</creatorcontrib><description>Introduction
The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.
Methods
Eligible for study participation were patients, without known cardiologic abnormalities who did not use cardiotoxic medication (except for ANT-therapy), who had previously completed at least three cycles of anthracyclin-containing chemotherapy (
n
= 14) and patients who were ANT-naïve and who were scheduled to receive doxorubicin-containing chemotherapy (
n
= 12). Seven patients in this last group also completed at least three cycles and were available for follow-up assessments; thus a total population of 21 patients (12F/9M) completed at least three courses ANT-chemotherapy. In these patients blood samples and ECG-recordings were taken within 6 months after completion of ANT-therapy. In 12 patients (10F/2M) assessments were also done before, immediately afterwards and at 24 h after each course of ANT.
Results and Conclusions
In the patients who completed chemotherapy, NT-proBNP was 277% (
n
= 21; 95% CI: 86–661%,
P
< 0.001) higher compared to healthy volunteers. During the first course NT-proBNP rose 269% (
n
= 12; 167–409%,
P
< 0.0001) at 24 h post-administration. The linear corrected QT (QTcL) directly after the first administration of ANT increased by 9.56 ms (
n
= 12; 3.85–15.27,
P
< 0.001) and this prolongation was still present at 24 h, 11.48 ms (
n
= 12; 5.61–17.34,
P
< 0.0001). Both NT-proBNP and QTcL returned to baseline before the start of the next course and a similar pattern was observed during each course. NT-proBNP and QTcL may be useful markers for course-to-course evaluation of anthracyclin-induced cardiotoxicity.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-008-0372-8</identifier><identifier>PMID: 18343950</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Anthracyclines - adverse effects ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers - blood ; Cancer ; Cancer Research ; Cardiovascular Diseases - chemically induced ; Cardiovascular system ; Chemotherapy ; Electrocardiography ; Female ; Hematology ; Humans ; Internal Medicine ; Male ; Medical diagnosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Paper ; Pharmacology. Drug treatments ; Side effects ; Toxicity</subject><ispartof>Journal of cancer research and clinical oncology, 2008-09, Vol.134 (9), p.961-968</ispartof><rights>The Author(s) 2008</rights><rights>2008 INIST-CNRS</rights><rights>Springer-Verlag 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-2e61e2de8e8515df4ff842dcc0a786830f479404f660e68b18d9aaa23c6a09e73</citedby><cites>FETCH-LOGICAL-c497t-2e61e2de8e8515df4ff842dcc0a786830f479404f660e68b18d9aaa23c6a09e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-008-0372-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-008-0372-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,778,782,883,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20584417$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18343950$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Broeyer, F. J. F.</creatorcontrib><creatorcontrib>Osanto, S.</creatorcontrib><creatorcontrib>Ritsema van Eck, H. J.</creatorcontrib><creatorcontrib>van Steijn, A. Q. M. J.</creatorcontrib><creatorcontrib>Ballieux, B. E. P. B.</creatorcontrib><creatorcontrib>Schoemaker, R. C.</creatorcontrib><creatorcontrib>Cohen, A. F.</creatorcontrib><creatorcontrib>Burggraaf, J.</creatorcontrib><title>Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Introduction
The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.
Methods
Eligible for study participation were patients, without known cardiologic abnormalities who did not use cardiotoxic medication (except for ANT-therapy), who had previously completed at least three cycles of anthracyclin-containing chemotherapy (
n
= 14) and patients who were ANT-naïve and who were scheduled to receive doxorubicin-containing chemotherapy (
n
= 12). Seven patients in this last group also completed at least three cycles and were available for follow-up assessments; thus a total population of 21 patients (12F/9M) completed at least three courses ANT-chemotherapy. In these patients blood samples and ECG-recordings were taken within 6 months after completion of ANT-therapy. In 12 patients (10F/2M) assessments were also done before, immediately afterwards and at 24 h after each course of ANT.
Results and Conclusions
In the patients who completed chemotherapy, NT-proBNP was 277% (
n
= 21; 95% CI: 86–661%,
P
< 0.001) higher compared to healthy volunteers. During the first course NT-proBNP rose 269% (
n
= 12; 167–409%,
P
< 0.0001) at 24 h post-administration. The linear corrected QT (QTcL) directly after the first administration of ANT increased by 9.56 ms (
n
= 12; 3.85–15.27,
P
< 0.001) and this prolongation was still present at 24 h, 11.48 ms (
n
= 12; 5.61–17.34,
P
< 0.0001). Both NT-proBNP and QTcL returned to baseline before the start of the next course and a similar pattern was observed during each course. NT-proBNP and QTcL may be useful markers for course-to-course evaluation of anthracyclin-induced cardiotoxicity.</description><subject>Anthracyclines - adverse effects</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cardiovascular Diseases - chemically induced</subject><subject>Cardiovascular system</subject><subject>Chemotherapy</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pharmacology. Drug treatments</subject><subject>Side effects</subject><subject>Toxicity</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kUtLxDAUhYMoOj5-gBspgsvqzaNtuhFEfIHoRtfhTprMRDvNmHTE-femzODowlVI7nfPOeQQckzhnAJUFxFAcJYDyBx4xXK5RUZ0eKGcF9tkBLSiecFouUf2Y3yDdC8qtkv2qOSC1wWMyNPNJ7YL7J3vMm-zsfMzDO8mxMz6kGkMjfO9_3La9csBwK6fBtRL3bouH2M0TaanZub7qQk4Xx6SHYttNEfr84C83t68XN_nj893D9dXj7kWddXnzJTUsMZIIwtaNFZYKwVrtAasZCk5WFHVAoQtSzClHFPZ1IjIuC4RalPxA3K50p0vxjPTaNP1AVs1Dy7FXyqPTv2ddG6qJv5TseRXyEHgdC0Q_MfCxF69-UXoUmbFGBSUCSETRFeQDj7GYOyPAQU1NKBWDajUgBoaUMPOye9km431lyfgbA1g1NjagJ128YdL5lIIOiRkKy6mUTcxYZPwf_dvzrqf0w</recordid><startdate>20080901</startdate><enddate>20080901</enddate><creator>Broeyer, F. J. F.</creator><creator>Osanto, S.</creator><creator>Ritsema van Eck, H. J.</creator><creator>van Steijn, A. Q. M. J.</creator><creator>Ballieux, B. E. P. B.</creator><creator>Schoemaker, R. C.</creator><creator>Cohen, A. F.</creator><creator>Burggraaf, J.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20080901</creationdate><title>Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy</title><author>Broeyer, F. J. F. ; Osanto, S. ; Ritsema van Eck, H. J. ; van Steijn, A. Q. M. J. ; Ballieux, B. E. P. B. ; Schoemaker, R. C. ; Cohen, A. F. ; Burggraaf, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-2e61e2de8e8515df4ff842dcc0a786830f479404f660e68b18d9aaa23c6a09e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Anthracyclines - adverse effects</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cardiovascular Diseases - chemically induced</topic><topic>Cardiovascular system</topic><topic>Chemotherapy</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pharmacology. Drug treatments</topic><topic>Side effects</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Broeyer, F. J. F.</creatorcontrib><creatorcontrib>Osanto, S.</creatorcontrib><creatorcontrib>Ritsema van Eck, H. J.</creatorcontrib><creatorcontrib>van Steijn, A. Q. M. J.</creatorcontrib><creatorcontrib>Ballieux, B. E. P. B.</creatorcontrib><creatorcontrib>Schoemaker, R. C.</creatorcontrib><creatorcontrib>Cohen, A. F.</creatorcontrib><creatorcontrib>Burggraaf, J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Broeyer, F. J. F.</au><au>Osanto, S.</au><au>Ritsema van Eck, H. J.</au><au>van Steijn, A. Q. M. J.</au><au>Ballieux, B. E. P. B.</au><au>Schoemaker, R. C.</au><au>Cohen, A. F.</au><au>Burggraaf, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2008-09-01</date><risdate>2008</risdate><volume>134</volume><issue>9</issue><spage>961</spage><epage>968</epage><pages>961-968</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Introduction
The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.
Methods
Eligible for study participation were patients, without known cardiologic abnormalities who did not use cardiotoxic medication (except for ANT-therapy), who had previously completed at least three cycles of anthracyclin-containing chemotherapy (
n
= 14) and patients who were ANT-naïve and who were scheduled to receive doxorubicin-containing chemotherapy (
n
= 12). Seven patients in this last group also completed at least three cycles and were available for follow-up assessments; thus a total population of 21 patients (12F/9M) completed at least three courses ANT-chemotherapy. In these patients blood samples and ECG-recordings were taken within 6 months after completion of ANT-therapy. In 12 patients (10F/2M) assessments were also done before, immediately afterwards and at 24 h after each course of ANT.
Results and Conclusions
In the patients who completed chemotherapy, NT-proBNP was 277% (
n
= 21; 95% CI: 86–661%,
P
< 0.001) higher compared to healthy volunteers. During the first course NT-proBNP rose 269% (
n
= 12; 167–409%,
P
< 0.0001) at 24 h post-administration. The linear corrected QT (QTcL) directly after the first administration of ANT increased by 9.56 ms (
n
= 12; 3.85–15.27,
P
< 0.001) and this prolongation was still present at 24 h, 11.48 ms (
n
= 12; 5.61–17.34,
P
< 0.0001). Both NT-proBNP and QTcL returned to baseline before the start of the next course and a similar pattern was observed during each course. NT-proBNP and QTcL may be useful markers for course-to-course evaluation of anthracyclin-induced cardiotoxicity.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18343950</pmid><doi>10.1007/s00432-008-0372-8</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2008-09, Vol.134 (9), p.961-968 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2515587 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Anthracyclines - adverse effects Antineoplastic agents Biological and medical sciences Biomarkers - blood Cancer Cancer Research Cardiovascular Diseases - chemically induced Cardiovascular system Chemotherapy Electrocardiography Female Hematology Humans Internal Medicine Male Medical diagnosis Medical sciences Medicine Medicine & Public Health Middle Aged Oncology Original Paper Pharmacology. Drug treatments Side effects Toxicity |
| title | Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T14%3A25%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20biomarkers%20for%20cardiotoxicity%20of%20anthracyclin-based%20chemotherapy&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Broeyer,%20F.%20J.%20F.&rft.date=2008-09-01&rft.volume=134&rft.issue=9&rft.spage=961&rft.epage=968&rft.pages=961-968&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-008-0372-8&rft_dat=%3Cproquest_pubme%3E1531673081%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220512448&rft_id=info:pmid/18343950&rfr_iscdi=true |